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Abstract
Purpose To follow choroidal thickness (ChT)
over time in birdshot retinochoroiditis (BRC)
using enhanced depth imaging optical
coherence tomography (EDI-OCT) and study
the effect of early and sustained treatment
on ChT.
Patients and methods Eighteen patients were
included and EDI-OCT measurements of ChT
were analyzed retrospectively in ﬁve groups
of patients with follow-up times ranging from
1 year to ≥ 15 years. The OCT images were
evaluated and ChT was calculated under the
foveola and 1500 μm temporal, nasal,
superior, and inferior to the foveola. To
assess the effect of treatment, 13 patients with
a disease duration ≥ 10 years were divided
into two groups depending on their treatment
status: early and sustained therapy vs
insufﬁcient, late, or no treatment. ChT was
compared in these two groups along with the
number of typical fundus BRC lesions.
Results The ChT decreased (r= –0.41,
P= 0.0018) over the disease duration, which
ranged from o1 year to ≥ 15 years. In
patients with a disease duration ≥ 10 years,
a signiﬁcant difference in ChT was noted
between adequately and undertreated
patients (288.3± 76.9 μm vs 161.4± 39.2 μm;
P= 0.004). At the last follow-up, in the group
with insufﬁcient therapy 10 of 11 eyes
presented typical fundus BRC lesions vs 2 of
13 eyes in the treated group (P≤ 0.0006,
F-test).
Conclusions Choroidal thickness decreases
signiﬁcantly over time in BRC. If undertreated,
patients show thinner choroids compared with
adequately treated individuals and present
signiﬁcantly more BRC lesions.
Eye (2017) 31, 1205–1211; doi:10.1038/eye.2017.54;
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Introduction
Birdshot retinochoroiditis (BRC) is a rare bilateral
autoimmune uveitis, with no apparent systemic
involvement, which mostly occurs in
Caucasians.1 It was ﬁrst described in 1980 by
Ryan and Maumenee, who named it2 and nearly
concomitantly by Gass, who called the disease
vitiliginous choroiditis.3 The typical clinical
appearance of the full-blown disease is
characterized by low, often subclinical anterior
segment inﬂammation, vitritis, retinal vasculitis
involving large veins as well as small retinal
capillaries,4 and rice-shaped hypopigmented
choroidal lesions (BRC lesions).5 We now know
that when PCR is used for detection, the HLA-
A29 antigen is present in almost 100% of cases
and has to be considered a required diagnostic
criterion. Indeed, HLA-A29 negative cases are
extremely rare.6–10 The availability of indocyanine
green angiography (ICGA) is another factor that
also changed our appraisal of BRC, as it can
provide precise information on choroidal
inﬂammatory involvement. Most importantly,
this method makes it possible to detect disease
activity in the choroid before it becomes clinically
evident by the appearance of BRC lesions. As a
result, more appropriate diagnostic criteria have
been put forward, allowing early diagnosis of
BRC.11 These include the presence of vitritis and
retinal vasculitis in one or both eyes, visual ﬁeld
anomalies in one or both eyes, stromal choroiditis
as evidenced by ICGA in both eyes (required),
HLA-A29 antigen positivity (required), and the
absence of extra-ocular inﬂammation sites. The
presence of BRC lesions is also strongly
suggestive of BRC but not requested anymore.11
BRC is unique in producing dual independent
inﬂammatory involvement of the choroid and
retina, with the latter being responsible for
disease morbidity and functional impairment due
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to inﬂammatory damage.1,12 Retinal involvement has been
studied using both ﬂuorescein angiography (FA) and
optical coherence tomography (OCT). Main FA signs in
early exudative disease include: retinal capillary leakage
with diffuse retinal edema involving the macula but less
prominent in the fovea, leakage along large veins seen in
late frames, and disc hyperﬂuorescence.1 At a later stage of
disease, FA shows diffuse thinning of vessels, including
arteries and veins, a consequence of extensive atrophic
retinal thinning, which can be partially avoided by early
and sustained inﬂammation suppressive treatment (IST).1
Optical coherence tomography is another approach for
examining retinal disease and provides a morphological
explanation for the retinal signs observed by FA. We
showed that in early disease, a diffusely thickened retina
was measured in the macula, although less so in the
fovea, which exhibited fewer ﬂuctuations in thickness
during disease progression.13 This supports the FA
ﬁnding that the fovea was relatively spared and that
visual acuity remained relatively conserved until late in
the disease. After a few years of disease progression, OCT
revealed areas of atrophy/thinning and thickening; while
in late disease, the mean retinal thickness was reduced
(mostly in patients for which IST had been delayed).13
Since the 1990s, the choroid can be explored by ICGA,
which made it possible to assess and monitor
inﬂammatory choroidal involvement in BRC by allowing
detection of occult choroidal lesions that were otherwise
inaccessible.14 Relevant ICGA signs for the diagnosis and
disease monitoring are the presence of hypoﬂuorescent
dark dots (HDDs) caused by stromal inﬂammatory foci,
and fuzzy large choroidal vessels, indicating vasculitis.15
In recent years, there has been substantial interest in
using enhanced depth imaging optical coherence
tomography (EDI-OCT) to potentially replace ICGA for
monitoring choroiditis.16 The EDI-OCT is a non-invasive
tool that can investigate the choroidal space, with the
capability to image deeper choroidal structures, enabling
quantitative measurements of choroidal thickness.17 The
disadvantage of EDI-OCT, or other choroidal OCT
devices that image deep choroidal structures, is their
inability to examine global pan-fundal choroidal
inﬂammation; thus, they cannot provide panoramic
information comparable to that generated by ICGA.18,19 It
was shown that EDI-OCT, unlike ICGA, was not suited
for precise and close visit-to-visit monitoring of
choroiditis during the acute phase of stromal choroiditis
when therapeutic adjustment was crucial;20 however, it
might become a useful method for the long-term follow-
up of stromal choroiditis such as BRC.21 The aim of this
study was to investigate the long-term evolution of
choroidal thickness in BRC patients and to verify whether
early and sustained IST management had a signiﬁcant
impact on the evolution of choroidal thickness.
Materials and methods
Patients
We surveyed 1793 cases of uveitis treated at the Centre for
Ophthalmic Specialized Care, Lausanne, Switzerland,
from 1995 to 2015 and retrieved all charts with the
diagnosis of BRC. For this study, we included all patients
for whom the EDI-OCT data were available. Patients were
subdivided into ﬁve groups according to the disease
duration—group 1: non-treated initial disease (o1 year
since the ﬁrst occurrence of symptoms), group 2: patients
with 1–4 years of evolution, group 3: patients with 5–9
years of evolution, group 4: patients with 10–14 years of
evolution, and group 5: patients with ≥ 15 years of
evolution. The exclusion criteria were as follows: (1) high
myopia or hyperopia (more than 6 diopters), (2) the
presence or history of choroidal neovascularization
secondary to BRC, (3) substantial media opacities
affecting visual acuity (that is, cataract) and the quality of
OCT-scans, and (4) a history of other retinal or choroidal
diseases. Patients with long follow-up periods, when
applicable, could be included in subsequent groups. The
study was performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki.
Diagnosis and treatment
The diagnosis of BRC was performed in accordance with
previously published diagnostic criteria.11 Brieﬂy, the
diagnosis of BRC was deﬁned as: retinal vasculitis in large
or small veins in one or both eyes; vitritis in one or both
eyes; visual ﬁeld abnormalities in one or both eyes; ICGA
lesions in both eyes (required); and the presence of HLA-
A29 antigen (required), with or without oval,
depigmented, birdshot lesions (BRC lesions). Adequate
treatment was deﬁned as follows: treatment within 1 year
after the occurrence of ﬁrst symptoms with systemic or
sub-Tenon’s steroids associated with
immunosuppressants, mostly mycophenolic acid
(Myfortic), cyclosporine, or azathioprine, and
corticosteroids being tapered to 0 or to o7.5 mg per day.
In case of insufﬁcient recovery of visual ﬁelds and/or the
persistence of retinal or choroidal inﬂammatory signs
(monitored by FA and ICGA), a second
immunosuppressant or biologic agent was added (for
example, anti-TNF-α treatment). Treatment was
maintained indeﬁnitely.
Outcome measures
In this study, the primary outcomes were as follows:
(1) the assessment of choroidal thickness evolution over
time and (2) in patients having a follow-up of ≥ 10 years, a
comparison of choroidal thickness for those who received
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early and sustained IST vs untreated patients or patients
treated insufﬁciently or late (undertreated group).
Secondary outcomes compared in these two groups
included the best-corrected visual acuity (BCVA), the
visual ﬁeld data (mean defect—MD), and the presence or
absence of BRC lesions at the last follow-up.
Clinical work-up
All patients underwent the routine complete work-up for
patients with uveitis, including a Snellen visual acuity
test, slit-lamp examination, applanation tonometry and
fundoscopy, laser ﬂare photometry (Kowa FM-500 or
FM-700 laser ﬂaremeter, Kowa Co., Tokyo, Japan),
computerized visual ﬁeld testing, enhanced depth
imaging optical coherence tomography (EDI-OCT), and
dual ﬂuorescein and ICGA (the latter not reported in this
study). Visual ﬁeld assessment was performed with a G1–
Program, OCTOPUS 900 (Octopus 900, G Standard;
Haag-Streit, Bern, Switzerland).
EDI-OCT
The EDI-OCT scans were obtained using a Heidelberg
Spectralis OCT (Heidelberg Engineering Inc., Heidelberg,
Germany). Choroidal thickness was measured manually
on EDI scans under the foveola and 1500 μm temporal (T),
nasal (N), superior (S), and inferior (I) to the foveola.
Choroidal thickness measurements were performed
perpendicular to the retinal pigmentary epithelium (RPE),
going from the posterior RPE edge to the choroid–scleral
junction. The mean thickness was established by
calculating the mean value of six measurements (under
the foveola and at 1500 μm T, N for the horizontal three
scans and under the foveola and at 1500 μm I, S for the
vertical three scans; mean of six values in total for each
eye measured). Evaluation of OCT scans and
measurements of choroidal thickness were conducted by
the same experienced observer (AG) and checked in a
blinded manner by an additional trained observer (BJ).
Difference in choroidal thickness (baseline visit minus
ﬁnal visit) was normalized to the baseline visit
measurement. Rate of choroidal thinning was set as
difference in choroidal thickness divided by the number
of months between baseline and ﬁnal follow-up visit.
Statistical analysis
The descriptive statistics used were the median and 95%
conﬁdence interval (CI) and the mean and SD. The Mann–
Whitney U test was used to compare the data in two
independent groups with abnormal distribution of data.
The multiple comparison of ChT in ﬁve groups was tested
by Analysis of Variation (ANOVA) with post hoc
Bonferroni correction. The difference in the presence of
BRC lesions was estimated using two-tailed Fisher’s exact
test. The degree of correlation was evaluated by Pearson
correlation coefﬁcient and Spearman correlation
coefﬁcient. The inter-observer variation was assessed
using the intraclass correlation coefﬁcient. Statistical
signiﬁcance was set at Po0.05. Analysis was performed
using MedCalc (version 15.2 for Windows; MedCalc
Software; Ostend, Belgium) and SPSS software version 23
(SPSS, Inc, Chicago, IL, USA).
Results
Demographics and clinical and functional data
Of the 1793 new cases of uveitis seen at the Centre for
Ophthalmic Specialized Care, Lausanne, Switzerland,
from 1995 to 2015, 29 (1.61%) had the diagnosis of BRC.
Among those patients, EDI-OCT data were available for
18 patients (10 women and 8 men). The median age at
disease onset was 57 years (95% CI: 51.5–62.5 years)
(range: 41–80 years). In all patients, the human leucocyte
histocompatibility antigen HLA-A29 was present (100%).
In the 13 patients with a follow-up of 10 years or more,
seven patients were considered to have received adequate
treatment and six were undertreated. Mean BCVA at
presentation was 0.96± 0.27 (range: 0.05 (amblyopia)–
1.25). Visual ﬁeld alterations (MD) at presentation was
7.75± 7.16 dB (range: − 1.1 to 24.9 dB). Visual acuity did
not show statistically signiﬁcant correlation with disease
duration (P= 0.55), while MD of visual ﬁeld had a low
degree correlation with the duration of BRC (r= 0.28,
P= 0.05). Mean laser ﬂare photometry values amounted
to 7.47± 6.04 ph/ms (range: 4.4–22.5 ph/ms), indicating
only subclinical anterior segment inﬂammation.
Signiﬁcant vitritis was observed at presentation in 6 of 18
cases (Diagnostic Criteria from Standardization of Uveitis
Nomenclature).
Evolution of choroidal thickness (EDI-ChT) over time
The intraclass correlation coefﬁcient was 0.921 (P= 0.001),
showing a high reliability in inter-observers’ manual
measurements. When analyzing all patients, choroidal
thickness decreased over time (r=− 0.41, P= 0.0018). In
the group with initial onset, untreated disease with o1
year duration of symptoms, the EDI-ChT was
375± 141 μm (No. of eyes= 6, mean time of
evolution= 3.3± 2.3 months), while it was 281± 120 μm
(No. of eyes= 6, mean time of evolution= 3.3± 0.6 years)
in group 2 (1–4 years of disease evolution), 249± 69.7 μm
(No. of eyes= 10; mean time of evolution= 7.8± 1.5 years)
in group 3 (5–9 years of evolution), 254± 75.6 μm (No. of
eyes= 16; mean time of evolution= 11.9± 1.3 years) in
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group 4 (10–14 years of evolution), and 209± 84.5 μm
(No. of eyes= 17 eyes, mean time of evolution= 16.8± 3.2
years) in group 5 (≥15 years of evolution). A repeated
measures ANOVA determined that mean ChT differed
statistically signiﬁcantly between 5 groups (F= 3.783,
P= 0.009). Post hoc tests using the Bonferroni correction
revealed the decrease of ChT during the disease duration.
The decrease of ChT was statistically signiﬁcant between
group 1 and group 5 (P= 0.004), whereas, it was
statistically insigniﬁcant among other groups. The
evolution of EDI-ChT is shown in Figure 1.
Comparison of EDI-ChT in adequately treated vs
undertreated patients with ≥ 10 years of evolution
Thirteen patients had an EDI-OCT performed after 10 or
more years of disease evolution (mean disease evolution
13.7± 3.7 years (range: 10–21 years). The clinical data of
patients are summarized in Table 1. Thirteen eyes (seven
patients) received early sustained systemic treatment
starting o1 year after initial symptoms, and eleven eyes
(six patients) did not receive any treatment (three
patients) or received delayed treatment (that is, ≥ 3 years
after the initial symptoms) or insufﬁcient treatment (three
patients). There were no signiﬁcant differences in age, sex,
disease duration, and refractive error between the two
groups (Table 2). The mean choroidal thickness in the
treated group was 288.3± 76.9 μm, while it was
161.4± 39.2 μm (P≤ 0.0001) in the undertreated group
(Figure 2). The average choroidal thinning for both
groups was 1.30 μm per month. Representative examples
of choroidal thickness from each group are shown in
Figures 3a and b.
A slightly lower BCVA was measured in the
undertreated group, compared with the treated group
(mean 0.8± 0.2 vs 1.0± 0.3, P≤ 0.0055). Visual ﬁeld
deterioration was less important in the treated group. The
MD values were 4.4± 2.7 dB in the treated group and
8.6± 8.5 dB in the undertreated group. However, the
difference did not reach statistical signiﬁcance because of
the small samples and the large standard deviations. In
the group with early and sustained treatment, only 2 of 13
eyes showed typical fundus BRC lesions at the last follow-
up, while 10 of 11 eyes with late or no treatment
presented typical BRC lesions (Figures 3c and d), a highly
statistically signiﬁcant ﬁnding (P≤ 0.00006, two-tailed
F-test).
Discussion
Birdshot retinochoroiditis is a chronic bilateral uveitis
affecting the retina and choroid. Presently, OCT
visualization enables clinicians to investigate the choroid
for better appraisal of the disease. Even though choroidal
thickness is affected by sex, age, axial length,22 and
systemic medications, several reports showed a
signiﬁcant decrease in the choroidal thickness in patients
with BRC compared with healthy individuals.23–25 Our
results are in agreement with previous short-term studies;
in this study, a substantial decrease of choroidal thickness
was noted in patients from disease onset to the long
period of disease evolution (415 years). We hypothesize
that the decrease of choroidal thickness is related to the
choroidal atrophy developed following the resolution of
choroidal inﬂammation. The same ﬁnding was observed
in another inﬂammatory disease affecting the choroid—
Vogt-Koyanagi-Harada (VKH) disease.18,21 Unlike to
BRC, VKH is more widespread and, consequently, more
studied. The typical sunset glow fundus appearance as a
result of undertreatment is associated with thinner
choroids compared to healthy controls.18
In addition to determining the progression of choroidal
thinning over time, our purpose was to investigate
whether early and sustained therapy had a long-term
effect in preventing thinning of the choroid. The
importance of early and sustained therapy has been put
forward previously by showing that it could prevent the
development of BRC lesions, changing the classical
phenotype of BRC.26 The typical ‘atrophic’ BRC lesions
occur in the choroid and represent areas devoid of
choroidal pigment after the inﬂammatory reaction against
it has subsided. It would be logical that less lesions would
translate into less global choroidal atrophy. Indeed,
patients with BRC treated aggressively had signiﬁcantly
less choroidal thinning in comparison with undertreated
patients. The mean choroidal thickness in the early and
sustained treatment group was maintained at
288.3± 76.9 μm, a fairly normal choroidal thickness.22,27
The difference in monthly choroidal thinning was
statistically insigniﬁcant for both groups and amounted to
Figure 1 Graph showing the evolution of choroidal thickness
during disease duration.
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1.30 μm that was less than 2.68 μm previously reported.24
This ﬁnding can be explained by disease duration: the
choroid thinning occurs with a greater rate in ﬁrst years of
BRC and after 10 years from disease onset, the choroidal
thickness decreases with the same rate in treated and
undertreated patients. We speculate that early treatment
leads to choroidal preservation in the ﬁrst 10 years of the
disease. Additionally, in contrast to adequately treated
patients, at the last follow-up, the presence of typical BRC
lesions was noted in 10 of 11 undertreated eyes, while
only 2 of 13 eyes in treated patients had such lesions at
this moment. In the undertreated group, BCVA was not
substantially diminished, conﬁrming that visual acuity is
not a good functional parameter to monitor disease
progression. The functional deterioration in the
undertreated group should probably be linked with
retinal morbidity caused by a less well controlled retinal
inﬂammatory process in the undertreated group.10 This
hypothesis is supported by our previous study on retinal
OCT analysis.13
The limitations of our study are the small number of
patients, which is a problem inherent to such a rare
disease, as well as its retrospective nature. Considering
the previous reports on OCT ﬁndings in BRC, there
were 2 more speciﬁc limitations: the lack of refractive
error information and the analysis of EDI-ChT without
correlation with treatment status.23,24 There are no
standard criteria for OCT analysis in patients with
choroidal inﬂammation; moreover, the absence of a
detailed protocol, which includes the difference of
various OCT instruments and software does not bring
clarity and make an issue for carrying out a multicenter
study. However, in this single-center study, we showed
that choroidal thickness is related not only to the
disease duration but also to the treatment status and
should be considered an additional important
parameter for the long-term follow-up of BRC. These
choroidal OCT ﬁndings add to the progress of
quantitative methods for evaluating posterior uveitis.
Furthermore, our results represent an additional
argument in favor of early and sustained treatment for
BRC.26,28
Table 1 Clinical data of patients with disease durations ≥ 10 years
Patient Age (years) Gender Disease duration (years) Treatment BCVA
Typical BRC
lesions
OD OS OD OS
1 63 M 10 Adequate 1 0.05a No No
2 65 F 11 Adequate 1 1.25 No No
3 57 M 11 Adequate Excluded 0.8 No No
4 60 F 11 Adequate 1.25 1.25 No No
5 65 F 14 Adequate 1.25 1.25 No No
6 63 F 13 Adequate 1.25 1.25 No No
7 70 F 21 Adequate 1 1 Yes Yes
8 72 F 11 Late/Insufﬁcient therapy 1 0.7 Yes Yes
9 70 F 11 Late/Insufﬁcient therapy 0.4 1 Yes Yes
10 80 F 12 None 0.5 0.7 No Yes
11 77 M 18 None Excluded 0.8 Yes Yes
12 70 M 19 None 1 1 Yes Yes
13 60 M 17 Late/Insufﬁcient therapy 0.9 0.6 Yes Yes
Abbreviation: BCVA, best-corrected visual acuity. a SD=Amblyopia.
Table 2 Demographics and clinical data for the treated and
undertreated groups
Treated group
(13 eyes)a
Undertreated
group (11 eyes)a
Age, years 63.3± 6.9 71.5± 6.9
Sex (M/F) 4/3 3/3
Disease duration, years 13± 3.7 14.6± 3.7
Refractive error, D +0.25± 2.0 − 0.75± 1.25
All the data are presented as the mean± SD. aOne eye excluded in each
group because of myopia 46 diopters.
Figure 2 Graph showing the difference in choroidal thickness
(μm) between the adequately treated and undertreated group.
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Summary
What was known before
K EDI-OCT measurement of choroidal thickness in birdshot
retinochoroiditis (BRC) has been reported in two articles in
2015 (11 patients) and in 2016 (8 patients), which both
showed decreased thickness in comparison to choroid of
healthy individuals.
What this study adds
K Thickness was put in relation with treatment and it was
shown that choroid is signiﬁcantly thinner in undertreated
patients. Patients adequately treated and conserved
choroidal thickness presented signiﬁcantly less BRC
fundus lesions.
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